Onco Wiki / drapeau rouge

Précédemment traités, récurrents, ou métastatiques, vulvaires ou carcinome de cellules squameuses vaginales...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-VULVAR-VAGINAL-SCC-PDL1-CPS-1-PLUS
TypeSignal d’alerte
Étatreviewed 2026-07-11 | pending_clinical_signoff
MaladiesDIS-VULVAR-VAGINAL-SCC
SourcesSRC-KEYNOTE-158-VULVAR-SHAPIRA-FROMMER-2022

Origine du drapeau rouge

DéfinitionPreviously treated, recurrent, or metastatic vulvar or vaginal squamous cell carcinoma with PD-L1 CPS ≥1 by 22C3 IHC. KEYNOTE-158 (Shapira-Frommer, Gynecol Oncol 2022) evaluated pembrolizumab monotherapy in previously treated advanced vulvar SCC (n=101): durable responses (ORR 10.9% overall, median DOR 20.4 months among responders) occurred in BOTH PD-L1-positive (ORR 9.5%, n=84) and PD-L1-negative (ORR 28.6%, n=7 — small subgroup, wide CI) patients. CPS≥1 is therefore NOT a validated hard predictive cutoff for vulvar SCC pembrolizumab response, unlike the CPS≥1 FDA-label requirement for cervical cancer (KEYNOTE-826). This RedFlag surfaces PD-L1 CPS status as an eligibility-informing (not strictly gating) marker for pembrolizumab access in metastatic/recurrent vulvar-vaginal SCC, consistent with cross-tumor pembrolizumab-eligibility practice pending a vulvar/vaginal-specific regulatory...
Direction cliniqueintensifier
Catégoriehigh-risk-biology
Algorithme de décalageALGO-VULVAR-VAGINAL-SCC-1L

Logique de déclenchement

{
  "any_of": [
    {
      "comparator": ">=",
      "finding": "pdl1_cps",
      "threshold": 1
    },
    {
      "comparator": ">=",
      "finding": "pdl1_cps_22c3",
      "threshold": 1
    },
    {
      "comparator": ">=",
      "finding": "BIO-PDL1-CPS",
      "threshold": 1
    }
  ],
  "type": "biomarker"
}

Notes

Severity set to 'minor' (lower than the analogous RF-CERVICAL-PDL1-CPS-1-PLUS, which is 'major') because the vulvar- SCC evidence base (KEYNOTE-158 basket cohort, n=101, non-randomized) does NOT show a clean PD-L1-positive vs PD-L1-negative response differential — unlike cervical cancer's KEYNOTE-826 randomized CPS≥1 stratification. This RF is authored as directed by the disease narrative ('metastatic — pembrolizumab if PD-L1+') for consistency with cross-tumor pembrolizumab-eligibility conventions in this KB, but the notes above make the evidentiary caveat explicit so a clinical reviewer can recalibrate severity/priority or the ALGO's routing logic. STUB pending clinical co-lead signoff (CHARTER §6.1; dev-mode-exempted per CHARTER §8.3 — draft content only).

Utilisé par

Algorithmes

Indication